iStock-1186615180_edited.jpg

Our DNA

 In 2008 a grand experiment was launched, not on a laboratory bench or in an exam room, but on an organization-wide scale. Mass General Brigham, formerly known as Partners HealthCare, committed $35 million to fund an internal venture capital arm to support the commercialization of home-grown technologies by establishing a direct path from hospital laboratories to the market. The strategic objective was to speed the passage of translational science to develop breakthrough medicines to enhance patient care.

We started with a bold idea and $35 million, and we have grown to be a market leader in the successful commercialization of technology from academic research. Today, we manage three funds totaling over $450 million in capital from internal and external sources. Limited partners include market-leading strategic investors, endowments, foundations, and private individuals. We have invested in 48 companies, realized 14 successful exits, and produced top-quartile venture returns. 

Leveraging

a proven approach

  • We invest exclusively in life science companies based on intellectual property created within our research community.

  • We generate a vast intellectual property estate fed by approximately 250 new patent applications each year.

 

  • The annual output of high-impact invention and discovery represents a unique opportunity to create, finance, and monetize new life science-based companies.

 

  • We deploy start-up capital to capture the collective expertise of our unrivaled base of scientific talent and clinical resources to bring cutting-edge science to patients.

 

  • We seek strong co-investor syndicates to build companies focused on drugs, devices, diagnostics, and digital health.

Legacy of innovation

Mass General Brigham hospitals share a legacy of innovation that includes 18 Nobel laureates and the development of therapies that have redefined the contemporary standard of care. The scope of the research enterprise is rooted in leadership and innovation spanning more than 150 years, as Mass General Brigham hospitals have been home to many of the world’s most notable medical advances. Below is a sampling of the hundreds of products, discoveries, and best practices originating at MGB hospitals, where a culture of innovation is ingrained in their missions. 

Etherdome

The Ether Dome, 1846

First X-Ray Machine, 1896

Organ transplant

First Organ Transplant, 1954

  • The world’s first public administration of the surgical use of anesthesia took place in Mass General Hospital’s Ether Dome on October 16, 1846. 

  • The first X-ray machine for medical use in the U.S. was made at Mass General Hospital in 1896. 

  • The world’s first organ transplant was performed in 1954 by Nobel laureate Dr. Joseph Murray at Peter Bent Brigham Hospital, one of three hospitals merged to form Brigham and Women’s Hospital. 

 

  • McLean Hospital scientists were the first to find cement-like protein polymers in the brain fibers of patients with Alzheimer’s disease. 

 

  • Brigham and Women’s Hospital investigators developed C-reactive protein (CRP), a widely ordered biomarker diagnostic test for cardiac risk. 

  • A team of investigators led by Mass General Hospital neurologist Dr. Rudolph Tanzi discovered four new Alzheimer’s disease gene candidates. 

  • Investigators at McLean Hospital’s Brain Imaging Center reported immediate and substantial mood improvement using low-field magnetic stimulation (LFMS)—a treatment unlike any other—for patients suffering from depression and bipolar disorder.